Breaking News

ABL Awarded NIH Contract to Support HIV Prevention Products

The seven-year contract has a total potential funding value of $98.9 million.

Advanced BioScience Laboratories (ABL), a global CDMO for biotherapies, oncolytics and viral vector vaccines, has been awarded a contract for ‘Resources to Advance Pediatrics and HIV Prevention Science (RAPPS)’ by the Division of AIDS (DAIDS) within the National Institute of Allergy and Infectious Disease (NIAID) at the National Institutes of Health (NIH). The seven-year contract has a total potential funding value of $98.9 million. ABL will provide DAIDS with preclinical gap-filling, animal ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters